Chengdu Olymvax Biopharmaceuticals Inc
SSE:688319
Income Statement
Earnings Waterfall
Chengdu Olymvax Biopharmaceuticals Inc
Revenue
|
548m
CNY
|
Cost of Revenue
|
-41.4m
CNY
|
Gross Profit
|
506.6m
CNY
|
Operating Expenses
|
-475.7m
CNY
|
Operating Income
|
30.9m
CNY
|
Other Expenses
|
-6.8m
CNY
|
Net Income
|
24.1m
CNY
|
Income Statement
Chengdu Olymvax Biopharmaceuticals Inc
Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||
Revenue |
320
N/A
|
355
+11%
|
378
+7%
|
405
+7%
|
487
+20%
|
477
-2%
|
551
+15%
|
573
+4%
|
548
-4%
|
561
+2%
|
548
-2%
|
|
Gross Profit | ||||||||||||
Cost of Revenue |
(18)
|
(17)
|
(19)
|
(24)
|
(28)
|
(31)
|
(38)
|
(39)
|
(43)
|
(47)
|
(41)
|
|
Gross Profit |
302
N/A
|
338
+12%
|
358
+6%
|
381
+6%
|
459
+20%
|
447
-3%
|
513
+15%
|
534
+4%
|
505
-6%
|
514
+2%
|
507
-1%
|
|
Operating Income | ||||||||||||
Operating Expenses |
(269)
|
(285)
|
(297)
|
(311)
|
(361)
|
(376)
|
(423)
|
(463)
|
(466)
|
(465)
|
(476)
|
|
Selling, General & Administrative |
(227)
|
(242)
|
(254)
|
(266)
|
(303)
|
(314)
|
(358)
|
(368)
|
(361)
|
(357)
|
(367)
|
|
Research & Development |
(40)
|
(43)
|
(46)
|
(43)
|
(50)
|
(60)
|
(65)
|
(93)
|
(113)
|
(124)
|
(132)
|
|
Depreciation & Amortization |
(7)
|
(4)
|
(5)
|
0
|
(11)
|
0
|
0
|
0
|
(14)
|
0
|
0
|
|
Other Operating Expenses |
5
|
3
|
9
|
(1)
|
3
|
(1)
|
(1)
|
(1)
|
22
|
17
|
23
|
|
Operating Income |
33
N/A
|
52
+58%
|
62
+18%
|
70
+13%
|
98
+39%
|
71
-28%
|
89
+26%
|
71
-20%
|
39
-46%
|
49
+27%
|
31
-37%
|
|
Pre-Tax Income | ||||||||||||
Interest Income Expense |
0
|
(0)
|
(1)
|
1
|
4
|
4
|
7
|
6
|
3
|
2
|
(1)
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
(0)
|
|
Total Other Income |
3
|
2
|
4
|
7
|
6
|
5
|
5
|
2
|
2
|
2
|
9
|
|
Pre-Tax Income |
36
N/A
|
54
+51%
|
65
+20%
|
78
+19%
|
107
+38%
|
80
-25%
|
101
+26%
|
80
-21%
|
44
-45%
|
54
+25%
|
39
-28%
|
|
Net Income | ||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
1
|
1
|
(4)
|
(9)
|
(17)
|
(19)
|
(17)
|
|
Income from Continuing Operations |
36
|
54
|
65
|
78
|
108
|
81
|
97
|
70
|
27
|
36
|
22
|
|
Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
|
Net Income (Common) |
36
N/A
|
54
+51%
|
65
+20%
|
78
+19%
|
108
+39%
|
81
-25%
|
97
+20%
|
70
-27%
|
27
-62%
|
37
+40%
|
24
-35%
|
|
EPS (Diluted) |
0.09
N/A
|
0.14
+56%
|
0.16
+14%
|
0.23
+44%
|
0.28
+22%
|
0.21
-25%
|
0.25
+19%
|
0.16
-36%
|
0.07
-56%
|
0.09
+29%
|
0.06
-33%
|